KineticVet Announces Availability of RE-COVR™

For Immediate Release May 24, 2022

RE-COVR™ (Tripelennamine Hydrochloride Injection)

Lexington, KY—RE-COVR™  KineticVet announces FDA approval of RE-COVR™ (tripelennamine hydrochloride injection), NADA # 006-417, supplied as a sterile solution in multiple dose vials (250 mL) containing 20 mg per mL.  RE-COVR™ is an injectable antihistamine indicated for use in cattle (beef & dairy) and horses.  It is approved for conditions in which antihistaminic therapy may be expected to lead to alleviation of some signs of disease.

RE-COVR™ Availability

RE-COVR™ is part of KineticVet’s commitment to deliver the latest product innovation.  It is available through your animal health supplier in a 250 mL (20 mg per mL) bottle.  For more information call 877-786-9882 or visit www.kineticvet.com.

Founded in 1999, KineticVet is a worldwide leader in innovative health care solutions for equine, bovine and companion animals offering a wide range of researched and result-oriented products and services. We are dedicated to innovation in product development.  KineticVet will strive to become a preferred supplier of customer-valued solutions.

###

KineticVet and RE-COVR are either registered trademarks or trademarks of KineticVet in the United States and/or other countries.

The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

For more information, press only:

Stuart L. Pierce, DVM

877-786-9882

info@kineticvet.com

For more information on RE-COVR™:

www.KineticVet.com